查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1999490

长效避孕药市场：依产品类型、作用持续时间、最终用户和通路划分－2026-2032年全球市场预测

Long-acting Contraception Market by Product Type, Duration Of Action, End User, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 180 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，长效避孕药市场价值将达到 39.4 亿美元，到 2026 年将成长至 42.1 亿美元，到 2032 年将达到 64.1 亿美元，复合年增长率为 7.21%。

主要市场统计数据
基准年 2025 39.4亿美元
预计年份：2026年 42.1亿美元
预测年份 2032 64.1亿美元
复合年增长率 (%) 7.21%

全面概述长效避孕技术、取得趋势以及影响临床和商业决策的相关人员需求。

在临床疗效、患者依从性优势以及不断变化的政策优先事项的驱动下，长效避孕技术已成为全球生殖健康策略的核心。本文说明了目前植入、注射避孕器和子宫内避孕器不仅是临床选择，更是减少意外怀孕和增强生育自主权的重要手段。除了技术进步之外，本文还探讨了服务模式的转变、报销压力和患者期望等因素，以阐明这些因素如何影响临床和零售环境中长效避孕技术的推广应用。

技术进步、服务交付创新以及不断变化的监管和报销重点如何重塑部署路径和竞争需求。

在技​​术创新、医疗体系变革和社会政治因素的共同推动下，长效避孕领域正在迅速变化。从结构改良的植入式避孕器、耐受性更佳的皮下注射，到新一代荷尔蒙避孕器，植入层面的改善正与数位化医疗工具结合，从而简化病患教育、知情同意和后续追踪流程。同时，医疗服务提供者也不断改进实践，强调分工、临床环境下的植入技术，以及将计划生育服务整合到更广泛的基层医疗工作流程中，这些都促进了长效避孕的普及。

评估 2025 年关税变化如何重塑整个製造和采购生态系统的筹资策略、价格形成动态和供应韧性。

进口关税和改变贸易流向的政策措施对製造商和医疗保健系统的产品供应、采购成本和策略采购决策产生了显着影响。 2025年美国征收的关税累积效应，增加了从受影响地区进口零件和成品的成本，从而给製造、分销和采购管道带来了新的营运压力。这促使许多製造商重新评估其企业发展区域，加快关键零件的在地采购，并调整商业合约价格，以在保障利润率的同时，维持其对产品供应的承诺。

将产品设计、临床交付环境和分销管道联繫起来的详细細項分析揭示了价值、获取和采用之间的交集。

细分市场分析揭示了每种产品类型、终端用户通路和通路的不同绩效驱动因素和商业性重点。就产品类型而言，植入以其持续疗效而着称，但其植入和取出需要经过密集的临床培训。在植入中，多桿系统和单桿系统之间的差异会影响医疗服务提供者的偏好、库存需求和病患咨询。对于注射药物，必须考虑给药环境和製剂特性。肌肉注射和皮下注射在低温运输需求、给药便利性和使用者接受度方面有明显差异。子宫内避孕器 (IUD) 呈现出两极分化的趋势，含铜子宫内避孕器吸引了寻求非荷尔蒙方案的用户，而含激素子宫内避孕器则在出血情况和作用持续时间方面展开竞争。

区域比较分析显示，美洲、欧洲、中东、非洲和亚太地区的监管复杂性、製造业投资和分销策略有何不同。

在美洲、欧洲、中东和非洲以及亚太地区这三大主要区域，区域趋势正在影响长效避孕药的监管发展、生产选择和分销策略。在美洲，政策重点和支付机制各不相同，一些地区的公共项目与其他地区由私人支付方主导的途径不尽相同，这影响着采购週期和商业合约方式。该地区的供应链中心正日益重视对本地生产的投资，以减少对跨洋运输的依赖和关税风险。同时，市场准入的成功取决于能否在实际应用中证明产品的安全性和成本效益。

以临床证据、生产规模和策略通路伙伴关係关係为中心的企业策略如何决定竞争地位。

该领域的企业层面行动的特点是投资于临床证据、生产规模和经销伙伴关係。主要企业优先考虑医疗设备的渐进式改进，以提高患者耐受性并简化插入和使用流程，同时透过上市后监测和可操作性研究累积证据。与契约製造和物流供应商建立策略合作伙伴关係正成为企业保护自身营运免受贸易中断影响并缩短新配方和改良型医疗设备上市时间的核心竞争优势。

製造商、支付方和医疗保健提供者应采取切实可行的策略重点，以确保供应弹性、扩大提供者能力并加快以患者为中心的医疗服务取得。

行业领导者必须采取果断行动，使产品开发、商业性执行和准入改进工作与不断变化的系统需求和患者期望保持一致。首先，他们必须优先考虑供应链多元化和紧急时应对计画，包括将关键零件近岸外包并建立替代性契约製造关係，以降低对特定供应商所在地的依赖以及关税波动的影响。其次，计划生育诊所、专科医疗机构和医院应投资于临床教育计画和工作共享计划，以降低推广应用的门槛并提升医疗服务提供者的能力。

透过高度透明和检验的研究设计来保证方法论的严谨性，该设计结合了对临床医生和采购负责人的初步访谈、监管证据和三角验证的二手资讯。

本分析所依据的研究透过系统性地回顾同侪审查的临床文献、监管文件、政策文件以及一手定性数据，建构了可靠的证据基础。一手研究包括对计划生育诊所、专科诊所和医院系统的临床医生进行结构化访谈，以及与采购经理、分销合作伙伴和医疗设备製造商进行对话，以检验营运假设。二手资讯提供了医疗设备发展、监管先例和公共采购机制的历史背景，并与一手证词进行交叉核对，以确保一致性并减少偏见。

结论强调需要协调产品、供应和交付策略，以扩大可及性并实现临床和商业性价值。

总之，长效避孕技术正处于临床创新与复杂商业性化实施的十字路口。持续进展取决于各方协调努力，将医疗设备的研发与切实可行的交付模式、稳健的生产体係以及以患者为中心的参与策略相结合。在未来的发展中，能够展现临床价值、确保策略供应链并根据当地医疗保健系统的实际情况调整分销方式的机构将更具优势。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章 长效避孕药市场：依产品类型划分

  • 植入
    • 多桿式植入
    • 单桿植入
  • 注射药物
    • 肌肉内注射
    • 皮下注射
  • 避孕器
    • 铜子宫内避孕器
    • 含激素子宫内避孕器

第九章 依作用时间分類的长效避孕药市场

  • 短期 LAC（1-3 个月）
  • 中期LAC（3-6个月）
  • 长期 LAC（1-5 年）

第十章 长效避孕药市场：依最终用户划分

  • 诊所
    • 计划生育诊所
    • 专科诊所
  • 医院
    • 私立医院
    • 公立医院

第十一章 长效避孕药市场：依通路划分

  • 医院药房
  • 在线的
    • 企业网站
    • 第三方平台
  • 零售药房
    • 连锁药局
    • 独立经营药房

第十二章 长效避孕药市场：依地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十三章 长效避孕药市场：依类别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十四章 长效避孕药市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十五章：美国长效避孕药市场

第十六章：中国长效避孕药市场

第十七章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • AbbVie Inc.
  • Afaxys, Inc.
  • Agile Therapeutics, Inc.
  • Bayer AG
  • Cipla Limited
  • CooperCompanies, Inc.
  • Gedeon Richter Plc
  • HLL Lifecare Ltd.
  • Incepta Pharmaceuticals Ltd.
  • Lupin Limited
  • Mayne Pharma Group Limited
  • Merck & Co., Inc.
  • Organon & Co.
  • Pfizer Inc.
  • Pregna International Ltd.
  • Shanghai Dahua Pharmaceutical Co., Ltd.
  • SMB Corporation Pvt. Ltd.
  • Sun Pharmaceutical Industries Ltd
  • Teva Pharmaceutical Industries Ltd
  • Theramex Ltd.
  • Viatris Inc
Product Code: MRR-563BF1FD02BB

The Long-acting Contraception Market was valued at USD 3.94 billion in 2025 and is projected to grow to USD 4.21 billion in 2026, with a CAGR of 7.21%, reaching USD 6.41 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 3.94 billion
Estimated Year [2026] USD 4.21 billion
Forecast Year [2032] USD 6.41 billion
CAGR (%) 7.21%

A comprehensive orientation to long-acting contraceptive technologies, access dynamics, and stakeholder imperatives shaping clinical and commercial decisions

Long-acting contraceptive technologies have become central to reproductive health strategies worldwide, driven by clinical efficacy, patient adherence advantages, and evolving policy priorities. This introduction situates the reader within the contemporary landscape where implants, injectables, and intrauterine devices are not only clinical options but also levers for reducing unintended pregnancy and enhancing reproductive autonomy. The discussion frames technological evolution alongside changing delivery models, reimbursement pressures, and patient expectations that together shape adoption pathways across clinical and retail settings.

Transitioning from clinical evidence to market execution requires attention to manufacturing agility, regulatory alignment, and distribution nuances. Innovations in implant design, injectable formulations, and intrauterine device materials have reduced barriers to uptake, yet access disparities persist due to supply chain fragmentation and heterogeneous provider capabilities. The introduction underscores the imperative for stakeholders to appreciate both clinical differentiators and commercial realities when planning product launches, scaling distribution, or forming public-private partnerships that expand access and ensure sustained supply continuity.

How technological advances, service delivery innovation, and evolving regulatory and reimbursement priorities are reshaping adoption pathways and competitive imperatives

The landscape of long-acting contraception is shifting rapidly under the influence of technological innovation, health-system transformation, and socio-political forces. Device-level improvements-ranging from refined implant architectures and subcutaneous injectables with enhanced tolerability to next-generation hormonal intrauterine options-are converging with digital health tools that streamline patient education, consent, and follow-up. These developments are complemented by evolving provider practices that emphasize task-sharing, point-of-care insertion competencies, and integrated family planning services within broader primary care workflows.

Concurrently, regulatory environments and reimbursement frameworks are adapting to prioritize access, safety surveillance, and real-world evidence generation. Telehealth and e-commerce channels are expanding touchpoints for counseling and product procurement, while supply chain optimization efforts, such as regional manufacturing and strategic inventory management, aim to reduce lead times and price volatility. Together, these transformative shifts are redefining competitive imperatives: product differentiation must now pair clinical advantage with proven distribution strategies, cost efficiency, and patient-centered engagement models to achieve durable adoption.

Assessment of how 2025 tariff changes have reconfigured sourcing strategies, pricing dynamics, and supply resilience across manufacturing and procurement ecosystems

Policy actions that alter import duties and trade flows have a measurable impact on the availability, procurement costs, and strategic sourcing decisions for manufacturers and health systems. The cumulative impact of tariffs introduced in 2025 in the United States has created new operational pressures across manufacturing, distribution, and procurement channels by increasing landed costs for components and finished devices imported from affected geographies. This has led many manufacturers to reassess geographic footprints, accelerate localization of critical components, and reprice commercial contracts to preserve margin while maintaining access commitments.

In response, healthcare purchasers and public buyers have emphasized supplier diversification and multi-sourcing strategies to mitigate tariff exposure. Likewise, manufacturers with vertically integrated capabilities or regional production assets have gained strategic latitude to reallocate inventory and stabilize supply lines. Importantly, these tariff-driven dynamics have intensified conversations about long-term supply resilience, the strategic value of nearshoring, and the need for contractual clauses that transparently allocate cost risk. For clinical programs and non-profit distributors that operate on constrained budgets, the tariffs have prompted renegotiations, procurement prioritization, and closer coordination with manufacturers to ensure treatment continuity and equitable access.

In-depth segmentation intelligence linking product design, clinical delivery settings, and distribution channels to reveal where value, access, and adoption intersect

Segment-level analysis reveals differentiated performance drivers and commercial priorities across product types, end-user channels, and distribution pathways. Based on product type, implants distinguish themselves through sustained efficacy and require focused clinical training for insertion and removal; within implants, the distinctions between multi-rod and single-rod systems influence provider preference, inventory requirements, and patient counseling. Injectables require attention to administration setting and formulation profile; intramuscular versus subcutaneous formats have distinct cold-chain considerations, ease of administration, and acceptability among users. Intrauterine devices present bifurcated dynamics where copper IUDs attract users seeking non-hormonal options while hormonal IUDs compete on bleeding profile and duration of action.

Based on end user, clinics and hospitals exhibit different procurement behaviors and service models. Family planning clinics prioritize cost-effective, high-throughput solutions and community outreach integration, whereas specialty clinics may emphasize advanced counseling and differentiated device portfolios. Private hospitals balance patient expectations and premium services with efficiency, while public hospitals operate under budgetary constraints and broader population health mandates. Based on distribution channel, hospital pharmacies remain central for inpatient and surgical settings; online channels-including company websites and third-party platforms-offer expanded counseling and discreet procurement options; and retail pharmacies, both chain and independent, provide accessible points of care and opportunities for pharmacist-led education. Integrating these segmentation lenses clarifies where clinical value, provider training, reimbursement design, and patient engagement must align to translate product attributes into sustained uptake and equitable access.

Comparative regional analysis showing how regulatory complexity, manufacturing investment, and channel strategies differ across the Americas, Europe Middle East & Africa, and Asia-Pacific

Regional dynamics shape regulatory trajectories, manufacturing choices, and channel strategies for long-acting contraception across three macro areas: the Americas, Europe Middle East & Africa, and Asia-Pacific. In the Americas, policy priorities and payer mechanisms vary from public programs in some jurisdictions to private payer-dominated access pathways in others, which influences procurement cadence and commercial contracting approaches. Supply chain nodes in the region are increasingly targeted for local production investments to reduce dependence on transoceanic shipping and tariff exposure, while market access success hinges on demonstration of real-world safety and cost-effectiveness.

In Europe Middle East & Africa, regulatory harmonization efforts coexist with diverse national reimbursement landscapes and infrastructure disparities. This requires adaptive market entry strategies that combine centralized regulatory filings where possible with tailored country-level engagement for public health purchasers and non-governmental providers. Capacity-building initiatives and donor-funded programs often shape demand in lower-resource settings across the region, necessitating affordable, robust devices and simplified service delivery models. In Asia-Pacific, demographic trends, varied health system maturity, and growing domestic manufacturing capabilities create both scale opportunities and competitive intensity. Regional strategies here emphasize cost-efficient production, partnerships with local distributors, and digital-first approaches to patient education and telehealth-enabled counseling. Across all regions, stakeholders must reconcile clinical innovation with pragmatic deployment pathways to ensure sustained access and equitable outcomes.

How corporate strategies centered on clinical evidence, manufacturing scale, and strategic channel partnerships are determining competitive positioning

Company-level behavior in this sector is defined by investments in clinical evidence, manufacturing scale, and distribution partnerships. Leading firms are prioritizing incremental device improvements that enhance patient tolerability and simplify insertion or administration while simultaneously building evidence through post-market surveillance and pragmatic studies. Strategic alliances with contract manufacturers and logistics providers have emerged as a core competency for firms that want to shield operations from trade disruptions and achieve faster time-to-market for new formulations or device variants.

Competition is also playing out through commercial partnerships with clinic networks, hospital systems, and pharmacy chains to secure preferential procurement agreements and integrated training programs for providers. Smaller, specialized entrants are differentiating through niche product design, targeted end-user education, and agile direct-to-consumer engagement via online channels. Meanwhile, larger incumbents leverage broad regulatory expertise to expedite approvals across multiple jurisdictions. Across the competitive landscape, companies that can couple technical innovation with scalable manufacturing, robust clinician training programs, and transparent supply commitments will preserve commercial advantages and deliver predictable access for health systems and patients.

Practical strategic priorities for manufacturers, payers, and providers to secure supply resilience, expand provider capacity, and accelerate patient-centered access

Industry leaders should act decisively to align product development, commercial execution, and access initiatives with evolving system requirements and patient expectations. First, prioritize supply chain diversification and contingency planning that reduce exposure to concentrated supplier nodes and tariff volatility, including nearshoring critical components and establishing backup contract manufacturing relationships. Next, invest in clinical education programs and task-sharing initiatives that reduce insertion barriers and expand provider capacity in family planning clinics, specialty settings, and hospitals alike.

Additionally, firms should harness digital channels to expand counseling and follow-up care, integrating telehealth touchpoints with in-person services to improve adherence and satisfaction. Pricing strategies must be constructed with transparency and flexibility to support public sector procurement while preserving sustainable margins for private sales. Finally, cultivate partnerships with health systems, non-profit organizations, and payers to co-create demonstration programs that generate pragmatic evidence and support reimbursement dialogues. Through these measures, companies can accelerate adoption, secure supply resilience, and expand equitable access while maintaining commercial viability.

Transparent and verifiable research design combining primary clinician and procurement interviews, regulatory evidence, and triangulated secondary sources to ensure methodological rigor

The research underpinning this analysis combined systematic review of peer-reviewed clinical literature, regulatory filings, policy documentation, and primary qualitative inputs to construct a robust evidence base. Primary research included structured interviews with clinicians across family planning clinics, specialty practices, and hospital systems, as well as conversations with procurement leaders, distribution partners, and device manufacturers to validate operational assumptions. Secondary sources provided historical context on device development, regulatory precedents, and public procurement mechanisms, and were triangulated against primary testimony to ensure consistency and reduce bias.

Analytical approaches included cross-segment synthesis to connect product attributes with end-user requirements and channel characteristics, and scenario analysis to explore risk exposures such as trade policy shifts and supply interruptions. Quality assurance processes involved double-coding of interview transcripts, independent methodological review, and sensitivity checks on qualitative inferences. Wherever possible, findings emphasize verifiable clinical endpoints, documented regulatory milestones, and observable procurement behaviors rather than speculative projections, ensuring that conclusions are grounded in replicable evidence and practitioner insights.

Concluding synthesis emphasizing the necessity of coordinated product, supply, and delivery strategies to expand access and realize clinical and commercial value

In conclusion, long-acting contraceptive technologies sit at the intersection of clinical innovation and complex commercial execution. Sustained progress will depend on coordinated efforts that align device development with pragmatic delivery models, resilient manufacturing footprints, and patient-centered engagement strategies. The trajectory ahead favors organizations that can simultaneously demonstrate clinical value, secure strategic supply arrangements, and adapt distribution approaches to local health system realities.

Stakeholders should view the current environment as an opportunity to invest in durable capabilities: robust post-market evidence generation, provider training and task-sharing programs, and partnerships that bridge commercial and public health priorities. By doing so, manufacturers, payers, and providers can expand access, improve health outcomes, and create differentiated, sustainable value propositions across diverse clinical and geographic settings.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Long-acting Contraception Market, by Product Type

  • 8.1. Implant
    • 8.1.1. Multi-Rod Implant
    • 8.1.2. Single-Rod Implant
  • 8.2. Injectable
    • 8.2.1. Intramuscular Injectable
    • 8.2.2. Subcutaneous Injectable
  • 8.3. Intrauterine Device
    • 8.3.1. Copper IUD
    • 8.3.2. Hormonal IUD

9. Long-acting Contraception Market, by Duration Of Action

  • 9.1. Short-term LAC (1-3 months)
  • 9.2. Medium-term LAC (3-6 months)
  • 9.3. Long-term LAC (1-5 years)

10. Long-acting Contraception Market, by End User

  • 10.1. Clinics
    • 10.1.1. Family Planning Clinic
    • 10.1.2. Specialty Clinic
  • 10.2. Hospitals
    • 10.2.1. Private Hospital
    • 10.2.2. Public Hospital

11. Long-acting Contraception Market, by Distribution Channel

  • 11.1. Hospital Pharmacy
  • 11.2. Online
    • 11.2.1. Company Website
    • 11.2.2. Third-Party Platform
  • 11.3. Retail Pharmacy
    • 11.3.1. Chain Pharmacy
    • 11.3.2. Independent Pharmacy

12. Long-acting Contraception Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Long-acting Contraception Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Long-acting Contraception Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Long-acting Contraception Market

16. China Long-acting Contraception Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. AbbVie Inc.
  • 17.6. Afaxys, Inc.
  • 17.7. Agile Therapeutics, Inc.
  • 17.8. Bayer AG
  • 17.9. Cipla Limited
  • 17.10. CooperCompanies, Inc.
  • 17.11. Gedeon Richter Plc
  • 17.12. HLL Lifecare Ltd.
  • 17.13. Incepta Pharmaceuticals Ltd.
  • 17.14. Lupin Limited
  • 17.15. Mayne Pharma Group Limited
  • 17.16. Merck & Co., Inc.
  • 17.17. Organon & Co.
  • 17.18. Pfizer Inc.
  • 17.19. Pregna International Ltd.
  • 17.20. Shanghai Dahua Pharmaceutical Co., Ltd.
  • 17.21. SMB Corporation Pvt. Ltd.
  • 17.22. Sun Pharmaceutical Industries Ltd
  • 17.23. Teva Pharmaceutical Industries Ltd
  • 17.24. Theramex Ltd.
  • 17.25. Viatris Inc

LIST OF FIGURES

  • FIGURE 1. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL LONG-ACTING CONTRACEPTION MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL LONG-ACTING CONTRACEPTION MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, BY DURATION OF ACTION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES LONG-ACTING CONTRACEPTION MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA LONG-ACTING CONTRACEPTION MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, BY IMPLANT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, BY IMPLANT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, BY IMPLANT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, BY IMPLANT, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, BY MULTI-ROD IMPLANT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, BY MULTI-ROD IMPLANT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, BY MULTI-ROD IMPLANT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, BY SINGLE-ROD IMPLANT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, BY SINGLE-ROD IMPLANT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, BY SINGLE-ROD IMPLANT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, BY INJECTABLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, BY INTRAMUSCULAR INJECTABLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, BY INTRAMUSCULAR INJECTABLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, BY INTRAMUSCULAR INJECTABLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, BY SUBCUTANEOUS INJECTABLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, BY SUBCUTANEOUS INJECTABLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, BY SUBCUTANEOUS INJECTABLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, BY INTRAUTERINE DEVICE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, BY INTRAUTERINE DEVICE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, BY INTRAUTERINE DEVICE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, BY INTRAUTERINE DEVICE, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, BY COPPER IUD, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, BY COPPER IUD, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, BY COPPER IUD, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, BY HORMONAL IUD, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, BY HORMONAL IUD, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, BY HORMONAL IUD, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, BY DURATION OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, BY SHORT-TERM LAC (1-3 MONTHS), BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, BY SHORT-TERM LAC (1-3 MONTHS), BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, BY SHORT-TERM LAC (1-3 MONTHS), BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, BY MEDIUM-TERM LAC (3-6 MONTHS), BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, BY MEDIUM-TERM LAC (3-6 MONTHS), BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, BY MEDIUM-TERM LAC (3-6 MONTHS), BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, BY LONG-TERM LAC (1-5 YEARS), BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, BY LONG-TERM LAC (1-5 YEARS), BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, BY LONG-TERM LAC (1-5 YEARS), BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, BY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, BY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, BY FAMILY PLANNING CLINIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, BY FAMILY PLANNING CLINIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, BY FAMILY PLANNING CLINIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, BY SPECIALTY CLINIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, BY SPECIALTY CLINIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, BY SPECIALTY CLINIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, BY PRIVATE HOSPITAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, BY PRIVATE HOSPITAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, BY PRIVATE HOSPITAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, BY PUBLIC HOSPITAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, BY PUBLIC HOSPITAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, BY PUBLIC HOSPITAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, BY ONLINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, BY ONLINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, BY ONLINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, BY ONLINE, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, BY COMPANY WEBSITE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, BY COMPANY WEBSITE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, BY COMPANY WEBSITE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, BY THIRD-PARTY PLATFORM, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, BY THIRD-PARTY PLATFORM, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, BY THIRD-PARTY PLATFORM, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, BY CHAIN PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, BY CHAIN PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, BY CHAIN PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, BY INDEPENDENT PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, BY INDEPENDENT PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, BY INDEPENDENT PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 89. AMERICAS LONG-ACTING CONTRACEPTION MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 90. AMERICAS LONG-ACTING CONTRACEPTION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 91. AMERICAS LONG-ACTING CONTRACEPTION MARKET SIZE, BY IMPLANT, 2018-2032 (USD MILLION)
  • TABLE 92. AMERICAS LONG-ACTING CONTRACEPTION MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 93. AMERICAS LONG-ACTING CONTRACEPTION MARKET SIZE, BY INTRAUTERINE DEVICE, 2018-2032 (USD MILLION)
  • TABLE 94. AMERICAS LONG-ACTING CONTRACEPTION MARKET SIZE, BY DURATION OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 95. AMERICAS LONG-ACTING CONTRACEPTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 96. AMERICAS LONG-ACTING CONTRACEPTION MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 97. AMERICAS LONG-ACTING CONTRACEPTION MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 98. AMERICAS LONG-ACTING CONTRACEPTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 99. AMERICAS LONG-ACTING CONTRACEPTION MARKET SIZE, BY ONLINE, 2018-2032 (USD MILLION)
  • TABLE 100. AMERICAS LONG-ACTING CONTRACEPTION MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 101. NORTH AMERICA LONG-ACTING CONTRACEPTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 102. NORTH AMERICA LONG-ACTING CONTRACEPTION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 103. NORTH AMERICA LONG-ACTING CONTRACEPTION MARKET SIZE, BY IMPLANT, 2018-2032 (USD MILLION)
  • TABLE 104. NORTH AMERICA LONG-ACTING CONTRACEPTION MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 105. NORTH AMERICA LONG-ACTING CONTRACEPTION MARKET SIZE, BY INTRAUTERINE DEVICE, 2018-2032 (USD MILLION)
  • TABLE 106. NORTH AMERICA LONG-ACTING CONTRACEPTION MARKET SIZE, BY DURATION OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 107. NORTH AMERICA LONG-ACTING CONTRACEPTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 108. NORTH AMERICA LONG-ACTING CONTRACEPTION MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 109. NORTH AMERICA LONG-ACTING CONTRACEPTION MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 110. NORTH AMERICA LONG-ACTING CONTRACEPTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 111. NORTH AMERICA LONG-ACTING CONTRACEPTION MARKET SIZE, BY ONLINE, 2018-2032 (USD MILLION)
  • TABLE 112. NORTH AMERICA LONG-ACTING CONTRACEPTION MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 113. LATIN AMERICA LONG-ACTING CONTRACEPTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 114. LATIN AMERICA LONG-ACTING CONTRACEPTION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 115. LATIN AMERICA LONG-ACTING CONTRACEPTION MARKET SIZE, BY IMPLANT, 2018-2032 (USD MILLION)
  • TABLE 116. LATIN AMERICA LONG-ACTING CONTRACEPTION MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 117. LATIN AMERICA LONG-ACTING CONTRACEPTION MARKET SIZE, BY INTRAUTERINE DEVICE, 2018-2032 (USD MILLION)
  • TABLE 118. LATIN AMERICA LONG-ACTING CONTRACEPTION MARKET SIZE, BY DURATION OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 119. LATIN AMERICA LONG-ACTING CONTRACEPTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 120. LATIN AMERICA LONG-ACTING CONTRACEPTION MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 121. LATIN AMERICA LONG-ACTING CONTRACEPTION MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 122. LATIN AMERICA LONG-ACTING CONTRACEPTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 123. LATIN AMERICA LONG-ACTING CONTRACEPTION MARKET SIZE, BY ONLINE, 2018-2032 (USD MILLION)
  • TABLE 124. LATIN AMERICA LONG-ACTING CONTRACEPTION MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 125. EUROPE, MIDDLE EAST & AFRICA LONG-ACTING CONTRACEPTION MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 126. EUROPE, MIDDLE EAST & AFRICA LONG-ACTING CONTRACEPTION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 127. EUROPE, MIDDLE EAST & AFRICA LONG-ACTING CONTRACEPTION MARKET SIZE, BY IMPLANT, 2018-2032 (USD MILLION)
  • TABLE 128. EUROPE, MIDDLE EAST & AFRICA LONG-ACTING CONTRACEPTION MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 129. EUROPE, MIDDLE EAST & AFRICA LONG-ACTING CONTRACEPTION MARKET SIZE, BY INTRAUTERINE DEVICE, 2018-2032 (USD MILLION)
  • TABLE 130. EUROPE, MIDDLE EAST & AFRICA LONG-ACTING CONTRACEPTION MARKET SIZE, BY DURATION OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 131. EUROPE, MIDDLE EAST & AFRICA LONG-ACTING CONTRACEPTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 132. EUROPE, MIDDLE EAST & AFRICA LONG-ACTING CONTRACEPTION MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 133. EUROPE, MIDDLE EAST & AFRICA LONG-ACTING CONTRACEPTION MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 134. EUROPE, MIDDLE EAST & AFRICA LONG-ACTING CONTRACEPTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 135. EUROPE, MIDDLE EAST & AFRICA LONG-ACTING CONTRACEPTION MARKET SIZE, BY ONLINE, 2018-2032 (USD MILLION)
  • TABLE 136. EUROPE, MIDDLE EAST & AFRICA LONG-ACTING CONTRACEPTION MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 137. EUROPE LONG-ACTING CONTRACEPTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 138. EUROPE LONG-ACTING CONTRACEPTION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 139. EUROPE LONG-ACTING CONTRACEPTION MARKET SIZE, BY IMPLANT, 2018-2032 (USD MILLION)
  • TABLE 140. EUROPE LONG-ACTING CONTRACEPTION MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 141. EUROPE LONG-ACTING CONTRACEPTION MARKET SIZE, BY INTRAUTERINE DEVICE, 2018-2032 (USD MILLION)
  • TABLE 142. EUROPE LONG-ACTING CONTRACEPTION MARKET SIZE, BY DURATION OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 143. EUROPE LONG-ACTING CONTRACEPTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 144. EUROPE LONG-ACTING CONTRACEPTION MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 145. EUROPE LONG-ACTING CONTRACEPTION MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 146. EUROPE LONG-ACTING CONTRACEPTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 147. EUROPE LONG-ACTING CONTRACEPTION MARKET SIZE, BY ONLINE, 2018-2032 (USD MILLION)
  • TABLE 148. EUROPE LONG-ACTING CONTRACEPTION MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 149. MIDDLE EAST LONG-ACTING CONTRACEPTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 150. MIDDLE EAST LONG-ACTING CONTRACEPTION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 151. MIDDLE EAST LONG-ACTING CONTRACEPTION MARKET SIZE, BY IMPLANT, 2018-2032 (USD MILLION)
  • TABLE 152. MIDDLE EAST LONG-ACTING CONTRACEPTION MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 153. MIDDLE EAST LONG-ACTING CONTRACEPTION MARKET SIZE, BY INTRAUTERINE DEVICE, 2018-2032 (USD MILLION)
  • TABLE 154. MIDDLE EAST LONG-ACTING CONTRACEPTION MARKET SIZE, BY DURATION OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 155. MIDDLE EAST LONG-ACTING CONTRACEPTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 156. MIDDLE EAST LONG-ACTING CONTRACEPTION MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 157. MIDDLE EAST LONG-ACTING CONTRACEPTION MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 158. MIDDLE EAST LONG-ACTING CONTRACEPTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 159. MIDDLE EAST LONG-ACTING CONTRACEPTION MARKET SIZE, BY ONLINE, 2018-2032 (USD MILLION)
  • TABLE 160. MIDDLE EAST LONG-ACTING CONTRACEPTION MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 161. AFRICA LONG-ACTING CONTRACEPTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 162. AFRICA LONG-ACTING CONTRACEPTION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 163. AFRICA LONG-ACTING CONTRACEPTION MARKET SIZE, BY IMPLANT, 2018-2032 (USD MILLION)
  • TABLE 164. AFRICA LONG-ACTING CONTRACEPTION MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 165. AFRICA LONG-ACTING CONTRACEPTION MARKET SIZE, BY INTRAUTERINE DEVICE, 2018-2032 (USD MILLION)
  • TABLE 166. AFRICA LONG-ACTING CONTRACEPTION MARKET SIZE, BY DURATION OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 167. AFRICA LONG-ACTING CONTRACEPTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 168. AFRICA LONG-ACTING CONTRACEPTION MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 169. AFRICA LONG-ACTING CONTRACEPTION MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 170. AFRICA LONG-ACTING CONTRACEPTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 171. AFRICA LONG-ACTING CONTRACEPTION MARKET SIZE, BY ONLINE, 2018-2032 (USD MILLION)
  • TABLE 172. AFRICA LONG-ACTING CONTRACEPTION MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 173. ASIA-PACIFIC LONG-ACTING CONTRACEPTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 174. ASIA-PACIFIC LONG-ACTING CONTRACEPTION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 175. ASIA-PACIFIC LONG-ACTING CONTRACEPTION MARKET SIZE, BY IMPLANT, 2018-2032 (USD MILLION)
  • TABLE 176. ASIA-PACIFIC LONG-ACTING CONTRACEPTION MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 177. ASIA-PACIFIC LONG-ACTING CONTRACEPTION MARKET SIZE, BY INTRAUTERINE DEVICE, 2018-2032 (USD MILLION)
  • TABLE 178. ASIA-PACIFIC LONG-ACTING CONTRACEPTION MARKET SIZE, BY DURATION OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 179. ASIA-PACIFIC LONG-ACTING CONTRACEPTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 180. ASIA-PACIFIC LONG-ACTING CONTRACEPTION MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 181. ASIA-PACIFIC LONG-ACTING CONTRACEPTION MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 182. ASIA-PACIFIC LONG-ACTING CONTRACEPTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 183. ASIA-PACIFIC LONG-ACTING CONTRACEPTION MARKET SIZE, BY ONLINE, 2018-2032 (USD MILLION)
  • TABLE 184. ASIA-PACIFIC LONG-ACTING CONTRACEPTION MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 185. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 186. ASEAN LONG-ACTING CONTRACEPTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 187. ASEAN LONG-ACTING CONTRACEPTION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 188. ASEAN LONG-ACTING CONTRACEPTION MARKET SIZE, BY IMPLANT, 2018-2032 (USD MILLION)
  • TABLE 189. ASEAN LONG-ACTING CONTRACEPTION MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 190. ASEAN LONG-ACTING CONTRACEPTION MARKET SIZE, BY INTRAUTERINE DEVICE, 2018-2032 (USD MILLION)
  • TABLE 191. ASEAN LONG-ACTING CONTRACEPTION MARKET SIZE, BY DURATION OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 192. ASEAN LONG-ACTING CONTRACEPTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 193. ASEAN LONG-ACTING CONTRACEPTION MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 194. ASEAN LONG-ACTING CONTRACEPTION MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 195. ASEAN LONG-ACTING CONTRACEPTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 196. ASEAN LONG-ACTING CONTRACEPTION MARKET SIZE, BY ONLINE, 2018-2032 (USD MILLION)
  • TABLE 197. ASEAN LONG-ACTING CONTRACEPTION MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 198. GCC LONG-ACTING CONTRACEPTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 199. GCC LONG-ACTING CONTRACEPTION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 200. GCC LONG-ACTING CONTRACEPTION MARKET SIZE, BY IMPLANT, 2018-2032 (USD MILLION)
  • TABLE 201. GCC LONG-ACTING CONTRACEPTION MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 202. GCC LONG-ACTING CONTRACEPTION MARKET SIZE, BY INTRAUTERINE DEVICE, 2018-2032 (USD MILLION)
  • TABLE 203. GCC LONG-ACTING CONTRACEPTION MARKET SIZE, BY DURATION OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 204. GCC LONG-ACTING CONTRACEPTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 205. GCC LONG-ACTING CONTRACEPTION MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 206. GCC LONG-ACTING CONTRACEPTION MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 207. GCC LONG-ACTING CONTRACEPTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 208. GCC LONG-ACTING CONTRACEPTION MARKET SIZE, BY ONLINE, 2018-2032 (USD MILLION)
  • TABLE 209. GCC LONG-ACTING CONTRACEPTION MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 210. EUROPEAN UNION LONG-ACTING CONTRACEPTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 211. EUROPEAN UNION LONG-ACTING CONTRACEPTION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 212. EUROPEAN UNION LONG-ACTING CONTRACEPTION MARKET SIZE, BY IMPLANT, 2018-2032 (USD MILLION)
  • TABLE 213. EUROPEAN UNION LONG-ACTING CONTRACEPTION MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 214. EUROPEAN UNION LONG-ACTING CONTRACEPTION MARKET SIZE, BY INTRAUTERINE DEVICE, 2018-2032 (USD MILLION)
  • TABLE 215. EUROPEAN UNION LONG-ACTING CONTRACEPTION MARKET SIZE, BY DURATION OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 216. EUROPEAN UNION LONG-ACTING CONTRACEPTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 217. EUROPEAN UNION LONG-ACTING CONTRACEPTION MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 218. EUROPEAN UNION LONG-ACTING CONTRACEPTION MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 219. EUROPEAN UNION LONG-ACTING CONTRACEPTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 220. EUROPEAN UNION LONG-ACTING CONTRACEPTION MARKET SIZE, BY ONLINE, 2018-2032 (USD MILLION)
  • TABLE 221. EUROPEAN UNION LONG-ACTING CONTRACEPTION MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 222. BRICS LONG-ACTING CONTRACEPTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 223. BRICS LONG-ACTING CONTRACEPTION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 224. BRICS LONG-ACTING CONTRACEPTION MARKET SIZE, BY IMPLANT, 2018-2032 (USD MILLION)
  • TABLE 225. BRICS LONG-ACTING CONTRACEPTION MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 226. BRICS LONG-ACTING CONTRACEPTION MARKET SIZE, BY INTRAUTERINE DEVICE, 2018-2032 (USD MILLION)
  • TABLE 227. BRICS LONG-ACTING CONTRACEPTION MARKET SIZE, BY DURATION OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 228. BRICS LONG-ACTING CONTRACEPTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 229. BRICS LONG-ACTING CONTRACEPTION MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 230. BRICS LONG-ACTING CONTRACEPTION MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 231. BRICS LONG-ACTING CONTRACEPTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 232. BRICS LONG-ACTING CONTRACEPTION MARKET SIZE, BY ONLINE, 2018-2032 (USD MILLION)
  • TABLE 233. BRICS LONG-ACTING CONTRACEPTION MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 234. G7 LONG-ACTING CONTRACEPTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 235. G7 LONG-ACTING CONTRACEPTION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 236. G7 LONG-ACTING CONTRACEPTION MARKET SIZE, BY IMPLANT, 2018-2032 (USD MILLION)
  • TABLE 237. G7 LONG-ACTING CONTRACEPTION MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 238. G7 LONG-ACTING CONTRACEPTION MARKET SIZE, BY INTRAUTERINE DEVICE, 2018-2032 (USD MILLION)
  • TABLE 239. G7 LONG-ACTING CONTRACEPTION MARKET SIZE, BY DURATION OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 240. G7 LONG-ACTING CONTRACEPTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 241. G7 LONG-ACTING CONTRACEPTION MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 242. G7 LONG-ACTING CONTRACEPTION MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 243. G7 LONG-ACTING CONTRACEPTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 244. G7 LONG-ACTING CONTRACEPTION MARKET SIZE, BY ONLINE, 2018-2032 (USD MILLION)
  • TABLE 245. G7 LONG-ACTING CONTRACEPTION MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 246. NATO LONG-ACTING CONTRACEPTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 247. NATO LONG-ACTING CONTRACEPTION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 248. NATO LONG-ACTING CONTRACEPTION MARKET SIZE, BY IMPLANT, 2018-2032 (USD MILLION)
  • TABLE 249. NATO LONG-ACTING CONTRACEPTION MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 250. NATO LONG-ACTING CONTRACEPTION MARKET SIZE, BY INTRAUTERINE DEVICE, 2018-2032 (USD MILLION)
  • TABLE 251. NATO LONG-ACTING CONTRACEPTION MARKET SIZE, BY DURATION OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 252. NATO LONG-ACTING CONTRACEPTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 253. NATO LONG-ACTING CONTRACEPTION MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 254. NATO LONG-ACTING CONTRACEPTION MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 255. NATO LONG-ACTING CONTRACEPTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 256. NATO LONG-ACTING CONTRACEPTION MARKET SIZE, BY ONLINE, 2018-2032 (USD MILLION)
  • TABLE 257. NATO LONG-ACTING CONTRACEPTION MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 258. GLOBAL LONG-ACTING CONTRACEPTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 259. UNITED STATES LONG-ACTING CONTRACEPTION MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 260. UNITED STATES LONG-ACTING CONTRACEPTION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 261. UNITED STATES LONG-ACTING CONTRACEPTION MARKET SIZE, BY IMPLANT, 2018-2032 (USD MILLION)
  • TABLE 262. UNITED STATES LONG-ACTING CONTRACEPTION MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 263. UNITED STATES LONG-ACTING CONTRACEPTION MARKET SIZE, BY INTRAUTERINE DEVICE, 2018-2032 (USD MILLION)
  • TABLE 264. UNITED STATES LONG-ACTING CONTRACEPTION MARKET SIZE, BY DURATION OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 265. UNITED STATES LONG-ACTING CONTRACEPTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 266. UNITED STATES LONG-ACTING CONTRACEPTION MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 267. UNITED STATES LONG-ACTING CONTRACEPTION MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 268. UNITED STATES LONG-ACTING CONTRACEPTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 269. UNITED STATES LONG-ACTING CONTRACEPTION MARKET SIZE, BY ONLINE, 2018-2032 (USD MILLION)
  • TABLE 270. UNITED STATES LONG-ACTING CONTRACEPTION MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 271. CHINA LONG-ACTING CONTRACEPTION MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 272. CHINA LONG-ACTING CONTRACEPTION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 273. CHINA LONG-ACTING CONTRACEPTION MARKET SIZE, BY IMPLANT, 2018-2032 (USD MILLION)
  • TABLE 274. CHINA LONG-ACTING CONTRACEPTION MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 275. CHINA LONG-ACTING CONTRACEPTION MARKET SIZE, BY INTRAUTERINE DEVICE, 2018-2032 (USD MILLION)
  • TABLE 276. CHINA LONG-ACTING CONTRACEPTION MARKET SIZE, BY DURATION OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 277. CHINA LONG-ACTING CONTRACEPTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 278. CHINA LONG-ACTING CONTRACEPTION MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 279. CHINA LONG-ACTING CONTRACEPTION MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 280. CHINA LONG-ACTING CONTRACEPTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 281. CHINA LONG-ACTING CONTRACEPTION MARKET SIZE, BY ONLINE, 2018-2032 (USD MILLION)
  • TABLE 282. CHINA LONG-ACTING CONTRACEPTION MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)